Drug Trial Radar · NCT03002935
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jan 2017
Primary completion
Mar 2017
Study completion Mar 2017
Sponsor
- Lead sponsor
- BPGbioIndustry
- Sponsor type
- Industry
- First posted
- Dec 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
Conditions
- Healthy
Interventions
BPM31510 Oral Nanosuspension 4%Drug
Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax)Time frame: Days 1, 2, 5, 15; baseline pre-dosing concentrations
- Area under the plasma concentration curve (AUC0-4)Time frame: Days 1, 2, 5, 15; baseline pre-dosing concentrations
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinilabs Inc.
Eatontown, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.